{"eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":22,"description":"Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.\n\nEtelcalcetide: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.","id":"EG000","otherNumAffected":2,"otherNumAtRisk":22,"seriousNumAffected":3,"seriousNumAtRisk":22,"title":"Study Participant"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1}],"term":"Cold Sores"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1}],"term":"Gastrointestinal Disorder"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1}],"term":"COVID-19 infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Cardiac event was experienced during an AVF revision under anesthesia.","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1}],"term":"Cardiac Event"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Subject was hospitalized for 2 weeks for vertigo/dizziness.","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1}],"term":"Vertigo/Dizziness"}],"timeFrame":"9 months after baseline"}